FDA Clears Abbott’s AI-Powered Coronary Imaging Platform

The US Meals and Drug Administration has cleared Abbott’s latest optical coherence tomography (OCT) imaging platform powered by its original Ultreon Application, the company has announced.

The machine is designed to produce a more comprehensive, computerized gaze of coronary blood vessels and doable blockages by combining OCT with synthetic intelligence (AI) detection.

A fresh watch by the company confirmed that physicians modified their treatment device in 88% of coronary artery blockages in step with added files from OCT vs angiography alone. 

“As cardiologists continue to undertake OCT and switch away from worn imaging methods equivalent to angiography, rising technologies are pivotal to search out out the suitable route of affected person care,” Nick West, MD, Abbott’s vascular chief clinical officer, acknowledged in the observation. “AI enables Ultreon Application to mechanically detect calcium and vessel diameters allowing doctors to keep stents precisely where they’re obligatory.” 

The machine bought CE imprint designation in April 2021.

Prepare Patrice Wendling on Twitter: @pwendl. For more from theheart.org | Medscape Cardiology, join us on Twitter and Facebook.